α1 Adrenoceptor subtypes: A synopsis of their pharmacology and molecular biology

Drug Development Research

Volumn 39, Issue 1, 1996, Pages 54-107

  Hancock, Arthur A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Adrenergic agonists; Adrenergic antagonists; Receptors, adrenergic, 1; Receptors, catecholamine; Sympathomimetics

Indexed keywords

1 (4 AMINO 6,7 DIMETHOXY 2 QUINAZOLINYL) 4 (BICYCLO[2.2.2]OCTA 2,5 DIEN 2 YLCARBONYL)PIPERAZINE; 5 METHYLURAPIDIL; ABANOQUIL; ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; BENEXTRAMINE; CHLOROETHYLCLONIDINE; CYCLAZOCINE; DOXAZOSIN; NIFEDIPINE; PHENOXYBENZAMINE; PHENYLEPHRINE; PRAZOSIN; RECEPTOR SUBTYPE; TERAZOSIN;

AMINO ACID SEQUENCE; BLOOD PRESSURE; CELL LINE; CYTOCHEMISTRY; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR CLONING; NONHUMAN; REVIEW; TISSUE SPECIFICITY; VASOCONSTRICTION;

EID: 0030497401     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(19960901)39:1<54::AID-DDR7>3.0.CO;2-J     Document Type: Review

References (376)

1. 1-apadrenoceptor. Pharmacol Commun 6:29-38.
2. 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br J Pharmacol 109:80-87.
3. 1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). Br J Urol 76:325-336.
4. Ahlquist RP (1948): A study of the adrenotropic receptors. Am J Physiol 153:586-600.
5. Al-Damluji S, Kopin IJ (1996): Binding and competitive inhibition of amine uptake at postsynaptic neurones (transport-P) by tricyclic antidepressants. Br J Pharmacol 117:811-816.
6. Andersson K-E (1993): Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45:253-308.
7. Andersson K-E (1994): Alphal adrenergic receptor blockade in the male lower urinary tract and other body systems. Scand J Urol Nephrol 29:13-20.
8. Anonymous (1996a): NS-49, Urological. Pharma Projects, m 1577.
9. Anonymous (1996b): Recordati's urologicals disappoint. Scrip 2129:25.
10. Aono J, Sakai K (1988): Investigations into the mechanism of the anti-hypertensive effect of SGB-1534, a novel ocpadrenoceptor antagonist, in rats. Jap J Pharmacol 48:229-239.
11. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MY Thod VE, Wilson C, Wilson S (1984): Atypical β-adrenoceptors on brown adipocytes as target for anti-obesity drugs. Nature 309:163-165.
12. Archibald JL, Baum T, Childress SJ (1970): l,4-Bis(2-indol-3-ylethyl) piperidines. J Med Chem 13:138-140.
13. Archibald JL, Alps BJ, Cavalla JF, Jackson JL (1971): Synthesis and hypotensive activity of benzamidopiperidylethylindoles. J Med Chem 14:1054-1059.
14. Archibald JL, Benke, GA (1974a): Benzainidopiperidines. 2. Heterocyclic compounds related to indoramin. J Med Chem 17:736-739.
15. Archibald JL, Fairbrother P, Jackson JL (1974b): Benzamidopiperidines. 3. Carbocyclic derivatives related to indoramin. J Med Chem 17:739-744.
16. Aubry ML, Davey MJ, Fetch B (1988): UK-52,046, a novel alphal-adrenoceptor antagonist with antidysrhythmic activity. Br J Pharmacol 95 (Suppl):752P.
17. 1-adrenoceptor subtypes mediate contraction in rabbit aorta and urethra. Eur J Pharmacol 287:153-161.
18. Axelrod FB, Krey L, Glickstein JS, Allison JW, Friedman D (1995): Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia. J Autonom Nerv Sys 55:29-35.
19. 1-adrenergic receptor subtypes modulate catecholamine-induced increases and decreases in ventricular automaticity. Circ Res 67:1535-1551.
20. Benfey BG, Yong MS, Belleau B, Melchiorre C (1979): Cardiac muscarinic blocking and atropinic blocking effects of a tetramine disulfide with α-adrenoceptor blocking activity. Can J Physiol Pharmacol 57:41-47.
21. Besset A, Chetrit M, Carlander B, Billiard M (1996): Use of modafinil in the treatment of narcolepsy: a long-term follow-up-study. Clin Neurophysiol 26:60-66.
22. 1-AR) subtype selectivity of orally administered drugs: Studies with RS 17053. FASEB J 9:613.
23. 1-AR) antagonists in dog prostate/blood pressure models. FASEB J 10:A425.
24. 1-adrenoceptors. Eur J Pharmacol 172:131-145.
25. Bognar IT, Enero MA (1988): Influence of a receptor reserve on the inhibition by calcium channel blockers of alpha adrenoceptor-mediated responses in rat isolated vascular tissues. J Pharmacol Exp Ther 245:673-681.
26. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S (1993): Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 16:46-53.
27. Bonacchi G, Agostini O, Fedi M, Bacciarelli C, Boni P, Castellucci A, Perretti F, Manzini S (1988): Resolution and pharmacological properties of the enantiomers of the potent α-adrenoceptor antagonist l-[2-ethoxy-2-(3′-pyridyl)ethyl]-4-(2′-methoxy-phenyl)piperazine. Arzneim-Forsch/Drug Res 38:650-654.
28. Browning C, Giles H, Martin GR (1995): The use of phenoxybenzamine to discriminate 5-HT receptors mediating endothelium-dependent and -independent vasorelaxation. Br J Pharmacol 116:262P.
29. Brune ME, Buckner SA, Polakowski J, Kerwin JF, Hancock AA (1995): Pharmacological antagonism of α-adrenergic agonist induced increases in canine intra-urethral pressure in vivo. Drug Dev Res 34:267-275.
30. 1-adrenergic antagonists on vascular and prostatic smooth muscle in intact conscious dogs. J Urology 155 (Suppl 88):332A.
31. 1a-adrenergic receptor. Biochem Biophys Res Commun 179:1485-1490.
32. Buckner S, Morse P, Ireland LM, Cain JC, Hancock AA (1996a): Receptor reserve in the isolated rat spleen, FASEB J 10:A424.
33. 1D-subtype. Eur J Pharmacol 297:241-248.
34. 2-adrenoceptors in rat vas deferens. Br J Pharmacol 108:336-341.
35. 1-adrenoceptor subtypes. Br J Pharmacol 112:208P
36. 1-adrenoceptor subtype-selective agonist. Life Sci 54:999-1007.
37. 1-adrenoceptor subtypes. Br J Pharmacol 117:703-711.
38. 1-adrenoceptors subtypes: Characterization, function and regulation. Acta Pharmacol Sinica 17:289-292.
39. Buyniski JP, Pircio AW, Schurig JE, Campbell JA (1980): Effects of tiodazosin, prazosin, trimazosin and phentolamine on blood pressure, heart rate and on pre- and postsynaptic α-adrenergic receptors in the rat. Clin Exp Hypertens 2:1039-1066.
40. Bylund DB (1985): Heterogeneity of alpha-2 adrenergic receptors. Pharmacol Biochem Behav 22:835-843.
41. Bylund DB, Ray-Prenger C (1987): ARC-239 is a selective antagonist at alpha-2B adrenergic receptors. Fed Proc 46:1445.
42. 2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol 42:1-5.
43. Bylund DB, Eikenberg DC, Hieble JP Langer SZ, Lefkowitz RJ, Minneman KP Molinoff PB, Ruffolo RR Jr, Trendelenburg U (1994): IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136.
44. 1-adrenoceptor antagonists and antihypertensive agents. J Med Chem 30:49-57.
45. 1-adrenoceptors on rabbit aorta. Eur J Pharmacol 241:141-148.
46. Castillo C, Castillo EF, Valencia I, Ibarra M, Bobadilla RA (1995): Droperidol interacts with vascular serotonin receptors and α-adrenoceptors. Arch Int Pharmacodyn 330:53-65.
47. Gauchie P Croons AM, Hubloux A (1995): A Belgian post-marketing study of terazosin for the treatment of benign prostate hypertrophy. Acta Therapeut 21:257-269.
48. 2-adrenoceptor blocking properties in addition to its alphas-adrenoceptor agonist activity. Br J Pharmacol 75:153P.
49. 1-adrenoceptor selectivity? Br J Urology 76 (Suppl 1):47-55.
50. 1-adrenoceptor subtypes in the human prostate. Br J Urol 74:58-5-589.
51. 1A-adrenoceptor antagonist: A metaanalysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29:155-167.
52. 1-adrenoceptor subtypes involved in the antinatriuretic response to intrarenal infusion of phenylephrine. Eur J Pharmacol 287:1-6.
53. Chen CC, Lin CE Huang YL, Ko FN, Teng, CM (1995): Bioactive constituents from the flower buds and peduncles of Lindera megaphylla. J Natural Prod 58:1423-1425.
54. Chess-Williams R, Jackson AH (1993): Receptor and tissue dependent effects of abanoquil (UK52046). Br J Pharmacol 108 (Suppl):115P.
55. 1A-Adrenoceptor subtype mediates contraction of the rat urethra. Br J Pharmacol 14:375-381.
56. 1-adrenoceptors of the rat vas deferens and spleen. Br J Pharmacol 116:205P.
57. 1-adrenoceptors of the human prostate. Br J Pharmacol 117:109P.
58. Chiu G, Fang J, Forray C, Borden LA, Adham N, Branchek TA, Bard JA, Weinshank RL, Hartig PR (1993): Synthesis of indoramin analogs: Pharmacological evaluation at cloned human (α-adrenergic receptors. Abstr Papers Am Chem Soc 206:50-MEDI.
59. Chueh S-C, Guh J-H, Chen J, Lai M-K, Ko F-N, Teng C-M (1996): Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur J Pharmacol 305:177-180.
60. 1-adrenoceptor classification scheme. Pharmacol Commun 6:9-14.
61. Coates J, Jahn U, Weetman DF (1982): The existence of a new subtype of α-adrenoceptor on the rat anococcygeus is revealed by SGD 101/75 and phenoxybenzamine. Br J Pharmacol 75:549-552.
62. Cohen ML, Wiley KW, Landry SAS (1980): In vitro comparison of the pre- and postsynaptic alpha adrenergic receptor blocking properties of prazosin and tiodazosin (BL5111). Clin Exp Hypertens 2:1067-1082.
63. Corsano S, Scapicchi R, Strappaghetti G, Marucci G, Paparelli F (1995): Novel and highly selective postsynaptic α-adrenoreceptor antagonists: Synthesis and structure-activity relationships of alkane-bridged[4-(phenoxyethyl)-l-piperazinyl]-3(2H)-pyridazinones. Eur J Med Chem 30:71-75.
64. 1-adrenergic receptor. Proc Natl Acad Sci USA 85:7159-7163.
65. 1-adrenergic receptor antagonists for the treatment of hypertension: Role of vascular alpha receptors in the control of peripheral resistance. Am Heart J 116:133-162.
66. Daniel EE, Low AM, Gaspar V, L-Chao H, Green J, Akrong J, Duerksen S, Soyka C, Chen CK, Boyd J, Kwan CY (1996): Unusual α-adrenoceptor subtype in canine saphenous vein: Comparison to mesenteric vein. Br J Pharmacol 117:1535-1543.
67. 3H]-Dihydroergocryptine binding in rat brain. Brain Res 132:327-336.
68. DeBernardis JF Winn M, Kerkman DJ, Kyncl JJ, Buckner S, Horrom B (1987): A new nasal decongestant, A-57219: A comparison with oxymetazoline. J Pharm Pharmacol 39:760-763.
69. 1 adrenoceptor subtypes in rats. J Pharmacol Exp Ther 276:1155-1161.
70. Docherty JR (1983): An investigation of presynaptic α-adrenoceptor subtypes in the pithed rat. Br J Pharmacol 78:655-658.
71. Doughty MB, Chu SS, Miller DW, Li K, Tessel RE (1990): Benextramine: A long-lasting neuropeptide Y receptor antagonist. Eur J Pharmacol 185:113-114.
72. 1-adrenoceptor mediated prostatic smooth muscle contraction. Urol Res 22:143-146.
73. Drew CM (1985): What do antagonists tell us about α-adrenoceptors? Clin Sci 68 (Suppl. 10):15S-19S.
74. Dubocovich ML, Langer SZ, Massingham R (1980): Lack of correlation between inhibition of noradrenaline release and end organ response during nerve stimulation. Br J Pharmacol 69:81-89.
75. Duteil J, Rambert FA, Pessonnier J, Bombert R, Assous E (1979): A possible α-adrenergic mechanism for drug (CRL40029)-induced hyperactivity. Eur J Pharmacol 59:121-123.
76. 1-adrenergic stimulation in relation to the behavior stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 180:49-58.
77. 1bAdrenoceptors mediate renal tubular sodium and water reabsorption in the rat. Br J Pharmacol 111:819-824.
78. Elhawary AM, Pettinger WA, Wolff DW (1992): Subtype-selective alphal-adrenoceptor alleviation in the rat kidney and its effect on the vascular presser response. J Pharmacol Exp Ther 260:709-713.
79. 1-adrenoceptor subtype mediating contraction of guinea-pig spleen. Eur J Pharmacol 260:211-220.
80. 1-adrenoceptors. Eur J Pharmacol 295:69-73.
81. 1B-adrenoceptor subtypes in vas deferens, kidney and aorta of the rat. Eur J Pharmacol 224:125-136.
82. 1A-adrenoceptors. Eur J Pharmacol 202:33-44.
83. 1-adrenoceptors that regulate contractile function: Subtypes and subcellular signal transduction mechanisms. Neurochem Res 21:217-229.
84. 1-adrenoceptors. Eur J Pharmacol 73:221-224.
85. 1-adrenergic receptor subtypes and signal transduction in SK-N-MC and NB41A3 neuronal cell lines. Mol Pharmacol 44:76-86.
86. 1-adrenoceptor classification. Eur J Pharmacol 268:141-149.
87. Flavahan NA, Vanhoutte PM (1986): α-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol Sci 7:347-349.
88. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288:201-207.
89. 1-adrenoceptors in isolated anococcygeus muscle of rat. Br J Pharmacol 109 (Suppl):112P.
90. 1A-AR antagonist, RS 17053. Br J Urol 114 (Suppl):P24.
91. 1-adrenoceptors in human prostate: Implications for adrenoceptor classification. Mol Pharmacol 49:209-215.
92. 1A-adrenoceptor? Br J Pharmacol 118:29P.
93. 1c-subtype. Mol Pharmacol 45:703-708.
94. Forray C, Chiu G, Wetzel JM, Bard JA, Weinshank RL, Branchek RA, Hartig P, Gluchowski C (1994b): Effects of novel alpha-1c adrenergic receptor antagonists on the contraction of human prostate smooth muscle. J Urol 151:267A.
95. Fouad-Tarazi FM, Okabe M, Goren H (1995): Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med 99:604-610.
96. Furnace G, Hamilton CA, Reid JL, Sumner DJ (1985): Recovery of α-adrenoreceptor mediated responses and binding site number after intravenous benextramine in the rabbit. J Auton Pharmacol 5:13-17.
97. 1-Adrenoceptor subtype mediating contractile responses of the human vas deferens. Br J Pharmacol 112 (Suppl):U71.
98. 1A-adrenoceptor-mediated responses of the rat and human vas deferens. Br J Pharmacol 115:127P.
99. 1A-Adrenoceptor-inediated contractile responses of the human vas deferens. Br J Pharmacol 116:1605-1610.
100. 3H]-methylurapidil. Mol Pharmacol 44:589-494.
101. García-Sαinz JA, Romero-Avila MT, Villalobos-Molina R, Minneman KP (1995): α1-Adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species. Eur J Pharmacol 289:1-7.
102. 1-adrenoceptor subtypes in the heart ventricular muscle of the rat. J Pharm Pharmacol 45:907-909.
103. Geller JC, Cua M, Prieto L, Guo S-D, Danilo P Jr, Rosen MR (1995): Chloroethylclonidine increases the incidence of lethal arrhythmias during coronary occlusion in anesthetized dogs. Eur J Pharmacol 294:423-428.
104. 1-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur J Med Chem 30 (Suppl):S299-S310.
105. 1B-adrencoeptor antagonist. Eur J Pharmacol. 287:13-16.
106. Gibbons JA, HancockAA, Vitt CR, Knepper S, Buckner SA, Brune ME, Milicic I, Kerwin JF, Richter LS, Taylor EW, Spear KL, Zuckermann RN, Spellmeyer DC, Braickman RA, Moos WH (1996): Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for α1-adrenoceptors. J Pharmacol Exp Ther 277:885-899.
107. Cleason MM, Hieble JP (1991): Ability of SK&F 104078 and SK&F 104856 to identify alpha-2 adrenoceptor subtypes in NCB20 cells and guinea pig lung. J Pharmacol Exp Ther 259:1124-1132.
108. 1adrenoceptors. Naunyn-Schmiedeberg Arch Pharmacol 318:1-9.
109. 1-adrenoceptors with extremely high affinity. Naunyn-Schmiedeberg Arch Pharmacol 321:7-10.
110. Godfraind T (1983): Actions of nifedipine on calcium fluxes and contraction in isolated rat arteries. J Pharmacol Exp Ther 224:443-450.
111. Goetz AS, Lutz MW, Rimele TJ, Saussy DL Jr (1994): Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes. J Pharmacol Exp Ther 271:1228-1233.
112. 1-adrenoceptors. Eur J Pharmacol 272:R5-R6.
113. 3H]-5-methyl-urapidil. Eur J Pharmacol 172:329-337.
114. 1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia: The concept of uroselectivity. Eur Urol 29:378-384.
115. 1-adrenergic receptor and identification of the hormone binding subunit. J Biol Chem 257:15174-15181.
116. 1-adrenergic receptor using a novel affinity resin. Proc Natl Acad Sci USA 79:2186-2190.
117. Greengrass R Bremner R (1979): Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 55:323-326.
118. 1A-adrenoceptor antagonist. Br J Pharmacol 104 (Suppl):321R
119. Gregoire JR, Sheps SG (1995): Newer antihypertensive drugs. Curr Opin Cardiol 10:445-449.
120. 1-adrenoceptor. Eur J Pharmacol 151:333-335.
121. 3H]-phenoxybenzamine. Biochem Biophys Res Commun 89:1178-1185.
122. 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br J Pharmacol 115:142-146.
123. Guh J-H, Ko F-N, Yu S-M, Wu Y-C, Teng C-M (1995b): Pharmacological evaluation of N-methyl-actinodaphnine, a new vascular Ot-adrenoceptor antagonist, isolated from Illigera luzonensis. Eur J Pharmacol 279:33-41.
124. 3H]-dihydroergocryptine to rat cardiac a-adrenoceptors. Br J Pharmacol 73:33-39.
125. Guilleminault C, Mignot E, Aldrich M, Quera-Salva MA, Tiberge M, Partinen M (1988): Prazosin is contraindicated in patients with narcolepsy. Lancet 609:511-512.
126. 1 adrenoceptor subtypes changes with age in the rat aorta. J Pharmacol Exp Ther 275:1656-1662.
127. 1-adrenergic receptors revealed by chlorethylclonidine. Mol Pharmacol 32:505-510.
128. 1-adrenergic receptor binding sites in rat tissues. Mol Pharmacol 40:531-538.
129. 1MF-2 and BC3H-1 clonalcell lines. Eur J Pharmacol 226:141-148.
130. Hancock AA, Hutchins CW, Basha FZ, DeBernardis JF (1991): Structure-activity relationships of imidazolines and related compounds at subtypes of Alpha-2 adrenergic receptors. FASEB J 5:A856.
131. Hancock AA, Buckner SA, Giardina WJ, Brune ME, Lee JY, Morse PA, Oheim KW, Stanisic DS, Warner RB, Kerkman DJ, DeBernardis JF (1995a): Preclinical pharmacological actions of (±)-(1'R*,3R*)-3-phenyl-l-[(1′,2′,3′, 4′-tetrahydro-5′,6′-methylene-dioxy-1′-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. J Pharmacol Exp Ther 272:1160-1169.
132. 2-adrenoceptors in vitro. J Recept Cell Signal Transduct Res 15:863-885.
133. 1-adrenoceptor binding sites in the rat heart: Subtype-selective agonists and antagonists. Br J Pharmacol 98:652P.
134. 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 97:691-700.
135. 3H]-prazosin binding sites. J Pharm Pharmacol 41:714-716.
136. 1-adrenoceptor antagonist HSR-175. Jap J Pharmacol 59:379-385.
137. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113:723-728.
138. 1-adrenergic responsiveness in intact cells by a new, irreversible receptor antagonist. Biochem Biophys Res Commun 142:403-409.
139. 1-adrenergic receptor: Synthesis and effects on membrane and affinity-purified receptors. Proc Natl Acad Sci USA 80:2102-2106.
140. Hibert ME Trumpp-Kallmeyer S, Bruinvels A, Hoflack J (1991): Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 40:8-15.
141. Hibert ME Trumpp-Kallmeyer S, Hoflack J, Bruinvels A (1993): This is not a G-protein-coupled receptor. Trends Pharmacol Sci 14:7-12.
142. 2-adrenoceptor subtype selectivity in tissue homogenates and cell lines. Pharmacologist 35:166.
143. Hieble JP, Boyce AJ, Gaine M (1986): Comparison of the α-adrenoceptor characteristics in human and canine prostate. Fed Proc 45:2609-2614.
144. Hieble JP Bondinell WE, Ruffolo RR Jr (1995a): α- and β-Adrenoceptors: From the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem 38:3415-3444.
145. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR (1995b): International Union of Pharmacology X Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update. Pharmacol Rev 47:267-270.
146. Hieble JP, McCafferty GP, Naselsky DP, Bergsma DJ, Ruffolo RR Jr (1995c): Recent progress in the pharmacotherapy of diseases of the lower urinary tract. Eur J Med Chem 30 (Suppl):269S-298S.
147. 1-adrenoceptors with a high affinity for WB4101 in rat lung. Br J Pharmacol 105:6-7.
148. 3H]-WB4101. J Receptor Res 14:75-98.
149. 1C-adrenergic receptor. Biochem Biophys Res Commun 195:902-909.
150. 1C-adrenoceptor splice variants. FEES Lett 363:256-260.
151. Huffman BB, Lefkowitz RJ (1980): [3H]-WB4101 - Caution about its role as an alpha-adrenergic subtype selective radioligand. Biochem Pharmacol 29:1537-1541.
152. Huffman BB, DeLean A, Wood CL, Schocken DD, Lefkowitz RJ (1979): Alpha-adrenergic receptor subtypes: Quantitative assessment by ligand binding. Life Sci 24:1739-1746.
153. Honda K, Nakagawa C (1986): Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 239:512-516.
154. 1-adrenoceptors. Naunyn-Schmiedeberg Arch Pharmacol 328:264-272.
155. 1-adrenergic receptor blocking activities of monatepil maleate, its metabolites and their enantiomers. Arzneim-Forsch/Drug Res 45:1057-1060.
156. 1-adrenoceptor subtypes in canine aorta, using alkylatingagents. Can J Physiol Pharmacol 72:97-103.
157. 1-adrenoceptor subtypes. Br J Pharmacol 116:1611-1618.
158. 1-adrenoceptor blocking properties of AR-C 239 in rats. Clin Exp Pharmacol Physiol 12:505-513.
159. Hutchins C (1994): Three-dimensional models of the D1 and D2 dopamine receptors. Endocr J 2:7-23.
160. Hutchins C (1996): Models of ligand binding and receptor function of the G protein-coupled receptors. In Schwartz TW, Hjorth SA, Kastrup JS (eds): Structure and Function of 7TM Receptors. Kopenhagen: Munksgaard, pp 213-226.
161. 1-adrenergic receptor subtype selective agonist binding. J Biol Chem 270:23189-23195.
162. 1 adrenergic receptor subtypes in receptor binding and functional models. FASEB J 9:A105.
163. 1-adrenoceptor subtypes. FASEB J 10:A418.
164. 1-adrenoceptor subtypes. Br J Pharmacol 107:184P.
165. 1-adrenergic receptor antagonist in kidney and MDCK cells. Hypertension 21:606.
166. James MK, Leighton HJ (1987): Analysis of putative Alpha-1s adrenoceptor agonism by Sgd 101/75 in the rat anococcygeus muscle. J Pharmacol Exp Ther 242:772-776.
167. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, BPHALF group (1993): Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12-18 month assessment. Br J Urol 72:615-620.
168. 1-adrenoceptor mediated pressor responses by calcium channel antagonists in the pithed rat. J Pharmacol Exp Ther 238:89-94.
169. 2C receptor antagonist. Naunyn-Schmiedeherg Arch Pharmacol 353 (Suppl):R90.
170. 1-adrenoceptor agonist, SDZ NVI-085, in guinea pigs. Eur J Pharmacol 285:313-315.
171. 3H]-phenoxybenzamine. Biochem Biophys Res Commun 91:303-311.
172. Karram MM, Partoll L, Rahe J (1996): Efficacy of nonsurgical therapy for urinary incontinence. J Reprod Med 41:215-219.
173. Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J (1988): Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 38:951-956.
174. Kawabe K (1993): Analysis of alpha-1 adrenoceptors in human prostate. Aktuel Urol 24:82-85.
175. Kawabe K (1995): Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 76 (Suppl 1):63-67.
176. 1-blocker, in the treatment of BPH (benign prostatic hyperplasia). Aktuel Urol 27:25-26.
177. Kawasaki T, Uenzono K, Abe I, Najamata S, Ueno M, Kawazoe N, Omae T (1981): Antihypertensive effect of E-642, a new alpha adrenergic blocking agent. Eur J Clin Pharmacol 20:399-405.
178. 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urololgy 44:52-57.
179. 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 115:981-986.
180. 1 adrenoceptors: Binding, functional and in vivo studies. Br J Pharmacol 118:871-878.
181. 1-adrenoceptors (AR). Soc Neurosci Abstr 20:526.
182. 1-adrenergic receptor subtypes: MDCK-D1 cells, but not rat cortical membranes possess a single population of receptors. Mol Pharmacol 39:407-413.
183. 1A receptor subtype. J Pharmacol Exp Ther 274:97-103.
184. Ko FN, Yu SM, Su MJ, Wu YC, Teng CM (1993): Pharmacological activity of (-)-discretamine, a novel vascular (α-adrenoceptor and 5-hydroxytryptamine receptor antagonist, isolated from Fissistigma glaucenscens. Br J Pharmacol 110:882-88.
185. 1D-adrenoceptor antagonist, isolated from Fissistigma glaucenscens. Br J Pharmacol 112:1174-1190.
186. 2-adrenergic receptor. Science 238:650-656.
187. 1A-adrenoceptor subtypes in rabbit: differentiation by a selective antagonist, HV723. Eur J Pharmacol 250:95-101.
188. 1-adrenoceptor subtypes involved in adrenergic contractions of dog blood vessels. Br J Pharmacol 112:1167-1173.
189. Kono M, Morita S, Rubsamen R (1995): Effects of α-adrenergic blockade on regional myocardial function in canine ischemic myocardium during β-adrenergic blockade. J Cardiothoracic Vase Anesthes 9:525-533.
190. Kontani H, Nakagawa M, Sakai T (1992): Effects of adrenergic agonists on an experimental urinary incontinence model in anesthetized rabbits. Jap J Pharmacol 58:339-346.
191. 3H]-tamsulosin in human hypertrophied prostate using computerized image analysis. Histochem J 27:1007-1013.
192. 1-adrenoceptors of rat tissues. J Pharmacol Exp Ther 249:70-77.
193. Kyncl JJ, Sonders RC, Sperzel WD, Winn M, Seely JH (1986): Terazosin. In Scriabine A (ed): New Cardiovascular Drugs 1986. New York: Raven Press, pp 1-18.
194. Kyncl JJ, Buckner SA, DeBernardis JF, Winn M, Brondyk H, Dudley RE (1987): Abbott-57219 [SCH-40054): A novel nasal decongestant. In Scriabine A (ed): New Cardiovascular Drugs 1987. New York: Raven Press, pp 251-259.
195. 1A-adrenoceptor in caudal artery of rat. Br J Pharmacol 116:300P.
196. 1A receptor antagonist properties. Eur J Pharmacol 297:83-86.
197. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG (1967): Differentiation of receptor systems activated by sympathomimetic amines. Nature (London) 214:597-598.
198. Langer SZ (1974): Presynaptic regulation of catecholamine release. Br J Pharmacol 60:481-497.
199. 1 adrenergic receptor subtypes. Cardiovasc Res 27:839-844.
200. 1-adrenergic receptors: Identification of the ligand binding subunit with a high affinity radioiodinated probe. J Biol Chem 259:2579-2587.
201. Lefèvre-Borg F Lechaire J, O'Connor S (1992): In vivo uroselectivity of alfuzosin compared to prazosin and terazosin. Br J Pharmacol 106 (Suppl):84P.
202. 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 109:1282-1298.
203. Lepor H, (1995): Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 22:375-386.
204. Lepor H, Tang R, Meretyk S, Shapiro E (1993a): Alphal adrenoceptor subtypes in the human prostate. J Urol 149:640-642.
205. Lepor H, Tang R, Shapiro E (1993b): The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22:301-307.
206. Lepor H, Zhang W, Kobayashi S, Tang R, Wang B, Shapiro E (1994): A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. J Pharmacol Exp Ther 270:722-727.
207. 1A-adrenoceptor in the human prostate. J Urol 154:2096-2099.
208. Levin RM, Ruggieri MR, Wein AJ (1988): Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. J Urol 139:844-848.
209. Lin JS, Roussel B, Akaoka H, Fort P Debilly G, Jouvet M (1992): Role of catecholamines in the modaflnil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 591:319-326.
210. 1-adrenergic agonists in myocardium from rats with postinfarction heart failure. Am J Physiol Heart Circ Physiol 38:H1553-H1563.
211. 1-adrenergic receptor: purification and characterization of the native receptor ligand binding subunit. J Biol Chem 261:7710-7716.
212. 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA 87:5094-5098.
213. 1A-adrenergic receptor. J Biol Chem 266:6365-6369.
214. Low AM, Bowdish DM, Prashad TR, Caspar V (1994): Interactions of chloroethylclonidine with rauwolscine- and prazosin-sensitive adrenoceptors in dogsaphenous vein. Br J Pharmacol 113:1263-1268.
215. Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C (1996): Safety profile of 3 months therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 29:29-35.
216. Lyon TF Randall WC (1980): Multiple central WB-4101 binding sites and the selectivity of prazosin. Life Sci 26:1121-1129.
217. 1B-adrenoceptor mediated components in the tension response of the rat vas deferens to electrical field stimulation. Br J Pharmacol 105:727-731.
218. 1B-adrenoceptors. Eur J Pharmacol 208:113-117.
219. 1C-adrenoceptor: Functional characterization in prostate. Br J Pharmacol 107 (Suppl):327P.
220. 1c-) adrenoceptor subtype. Br J Pharmacol 115:781-786.
221. 1A-adrenoceptors between rat tissues. Br J Pharmacol 117:110P.
222. Martin D, Jammes D, Angel I (1995): Effects of alfuzosin on urethral and blood pressures in conscious male rats. Life Sci 57:387-391.
223. Massi M, Venturi F, Brasili L, Melchiorre C (1986): Hypotensive effect in dogs and rats of intravenous injections of the α1-adrenoreceptor antagonist benoxathian. Pharmacol Res Commun 18:813-829.
224. 2-adrenoceptors. Br J Pharmacol 81:255-262.
225. McTavish D, Goa KL (1989): Midodrine: A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 38:757-777.
226. Melchiorre C, Young MS, Benfey BG, Belleau B (1978): Molecular properties of the adrenergic receptor. 2. Optimum covalent inhibition by two different prototypes of polyamine disulphides. J Med Chem 21:1126-1132.
227. 1-adrenoceptors. J Med Chem 27:1535-1536.
228. Merritt JE, Armstrong WP, Benham CD, Hallam RJ, Jacob R, Jaxa-Chamiec A, Leigh BK McCarthy, SA, Moores KE, Rink RJ (1990): SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J 271:515-522.
229. 1"-adrenoceptors in rat brain. Naunyn-Schmiedeberg Arch Pharmacol 312:23-26.
230. 1-adrenoceptors. Br J Pharmacol 112:U32.
231. 1A-subtype in rat submaxillary gland. Br J Pharmacol 98:883-889.
232. 2-adrenoceptor subtypes. Mol Pharmacol 44:1165-1170.
233. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg Arch Pharmacol 352:1-10.
234. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 16:21-28.
235. 1 adrenoceptor subtypes in narcolepsy-cataplexy: A disorder of REM sleep. Brain Res 490:186-191.
236. Mignot E, Nishino S, Guilleminault C, Dement WC (1994): Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17:436-437.
237. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91:10109-10113.
238. 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging. Mech Ageing Dev 87:75-89.
239. Miller SM, Simon RJ, Ng S, Zuckermann RN, Kerr JM, Moos WM (1994): Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. Bioorg Med Chem Lett 4:2657-2662.
240. 2+. Pharmacol Rev 40:87-119.
241. 1-Adrenergic receptor subtypes. Annu Rev Pharmacol Toxicol 34:117-133.
242. 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. Mol Pharmacol 33:509-514.
243. 1-adrenergic receptor subtypes. Mol Pharmacol 46:929-936.
244. Mitchell PB (1995): Novel French antidepressants not available in the United States. Psychopharmacol Bull 31:509-519.
245. 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens 7:1315-1405.
246. 1A Ligands. Arch Pharmacol 327:529-531.
247. Moriyama N, Miyata N, Yamaura H, Yamazaki R, Tsuchida K, Hurimoto S, Nagase Y, Ishida Y, Kawabe K (1994): Multidirectional contraction of human hypertrophied prostate. Gen Pharmacol 25:1459-1464.
248. 1 receptor binding sites in rat brain. Eur J Pharmacol 109:285-287.
249. 2-adrenoceptor antagonist in guinea-pit ileum. Gen Pharmacol 16:367-370.
250. Müller-Schweinitzer E (1983): Tissue specific susceptibility of alpha-adrenoceptor mediated vasoconstriction to nifedipine. Naunyn-Schmiedeberg Arch Pharmacol 324:64-69.
251. 1-adrenoceptors in noradrenaline contraction of the rabbit thoracic aorta. Br J Pharmacol 101:662-666.
252. 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol 99:197-201.
253. 1-adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery. Br J Pharmacol 57:535-544.
254. 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 784:572-578.
255. 1-adrenoceptors. Pharmacol Commun 6:23-28.
256. 1-adrenoceptor subtypes. Naunyn-Schmidieberg Arch Pharmacol 351:2-9.
257. 1-adrenoceptor antagonist, JTH-601: Comparison with prazosin. Eur J Pharmacol 300:155-157.
258. Murphy TJ, Bylund DB (1988): Characterization of alpha-2 adrenergic receptors in the OK cell, an opossum kidney cell line. J Pharmacol Exp Ther 244:571-578.
259. Nicolaidis S, de Saint Hilaire Z (1993): Nonamphetamine awakening agent modafinil induces feeding changes in the rat. Brain Res Bull 32:87-90.
260. Nishino S, Fruhstorfer B, Arrigoni J, Guilleminault C, Dement WC, Mignot E (1993): Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther 264:1079-1084.
261. Nito H (1994): Clinical effect of midodrine hydrochloride on the patients with urinary incontinence. Hinyokika Kiyo 40:91-94.
262. 1-adrenoceptor subtypes. Br J Pharmacol 114:26P.
263. 1-adrenoceptors. J Urol 155:588A.
264. Noguchi H, Muraoka R, Kigoshi S, Muramatsu I (1995): Pharmacological characterization of α1-adrenoceptor subtypes in rat heart: A binding study. Br J Pharmacol 114:1026-1030.
265. 1-adrenoceptor agonists. Res Commun Mol Pathol Pharmacol 92:31-42.
266. 2-adrenoceptors in the dog saphenous vein. Naunyn-Schmiedeberg Arch Pharmacol 348:264-258.
267. Oates HF Stoker LM (1979): A new prazosin analogue BL-5111A. Arch Int Pharmacodyn Ther 240:305-313.
268. 1-adrenoceptors. Eur J Pharmacol 291:327-334.
269. 1-adrenoceptor subtypes in the rat vas deferens: Binding and functional studies. Br J Pharmacol 107:697-704.
270. 1-adrenoceptor subtypes in the dog prostate. Jap J Pharmacol 58:174P.
271. 1-adrenoceptor subtypes in the dog prostate. Urol Res 21:211-215.
272. 2+ entry blocker, AJ-2615, in vitro. J Cardiovasc Pharmacol 22:804-809.
273. O'Rourke M, Kearns S, Docherty JR (1995): Investigation of the actions of chloroethylclonidine in rat aorta. Br J Pharmacol 115:1399-1406.
274. 1-adrenoceptor subtypes and causes relaxation of arterial smooth muscle by raising cGMP levels. Br J Pharmacol 115:215P.
275. 1-adrenoceptor subtypes in rabbit thoracic aorta. Br J Pharmacol 108:1071-1076.
276. 1-adrenoceptor antagonist, anti-arrhythmic. Drugs Future 17:983-986.
277. 1D-adrenergic receptor cDNA. Mol Pharmacol 40:876-883.
278. Perez DM, Hwa J, Gaivin R, Mathur M, Brown E Graham RM (1996): Constitutive activation of a single effector pathway: Evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 49:112-122.
279. 3H-dihydroergokryptine in calf brain: Implications fora two-site model of alpha receptor function. Mol Pharmacol 14:403-412.
280. 1-adrenoceptor subtypes in the regulation of arterial blood pressure. Eur J Pharmacol 180:381-386.
281. 1-Adrenoceptor subtypes and the regulation of peripheral hemodynamics in the conscious rat. Eur J Pharmacol 180:273-278.
282. Piascik MT, Smith MS, Barron KW, Soltis (1993): EE The regulation of regional hemodynamics by alpha-1 adrenoceptor subtypes in the conscious rat. J Pharmacol Exp Ther 267:1250-1255.
283. Piérard C, Satabin P, Lagarde D, Barrère B, Guezenneec CY, Menu JP, Pérès M (1995): Effects of a vigilance-enhancing drug, modafinil, on rat brain metabolism: A 2D COSY 1H-NMR studv. Brain Res 693:251-256.
284. Pittner H, Stormann J, Enzenhofer R (1976): Pharmacodynamic actions of midodrine, a new α-adrenergic stimulating agent, and its main metabolite, ST 1059. Arzneim-Forsch/Drug Res 26:2145-2154.
285. Piwinski SE, Jankovic J, McElligott MA (1994): A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomie failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol 34:466-471.
286. 1 adrenergic receptor subtypes in human prostate. J Urol 150:546-551.
287. Quaglia W, Pigini M, Tayebati SK, Piergentili A, Giannella M, Marucci G, Melchiorre C (1993): Structure-activity relationships in 1,4-benzodioxan-related compounds. 4. Effect of aryl and alkyl substituants at position 3 on α-adrenoceptor blocking activity. J Med Chem 36:1520-1528.
288. Quaglia W, Giannella M, Marucci G, Piergentili A, Pigini M, Tayebati SK, Melchiorre C (1996): Structure-activity relationships in 1,4-benzodioxan-related compounds. 5. Effects of modification of the side chain on α-adrenoceptor blocking activity. II Farmaco 51:27-32.
289. 1A-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. Drugs Today 32:259-268.
290. Ramage AG, Wyllie MG (1995): A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats. Eur J Pharmacol 294:645-650.
291. 1B-adrenergic receptor. J Biol Chem 267:21936-4 21945.
292. 1-adrenoceptor occupancy decreases relaxing potency of nifedipine by increasing myosin light chain phosphorylation. Circ Res 72:1308-1316.
293. 2-adrenergic receptor subtype. Proc Natl Acad Sci USA 85:6301-6305.
294. 1-agonist, on canine cateplexy; a disorder of rapid eye movement sleep. Eur J Pharmacol 205:11-16.
295. 1-adrenoceptor-mediated second messenger responses in rat cerebral cortex slices. Br J Pharmacol 100:3-4.
296. 1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. J Biol Chem 271:5839-5843.
297. 1A-receptors. Eur J Med Chem 24:499-504.
298. 1-adrenoceptors. II Farmaco 50:471-477.
299. Ross RJ, Gresch PJ, Ball WA, Sanford LD, Morrison AR (1995): REM sleep inhibition by desipramine: Evidence for an α-1 adrenergic mechanism. Brain Res 701:129-134.
300. 1-Adrenoceptors. Pharmacol Ther 61:1-64.
301. Ruffolo RR Jr, Waddell JE (1982): Receptor interactions of imidazolines. IX. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist. J Pharmacol Exp Ther 222:29-36.
302. Ruffolo RR Jr, Morgan EL, Messick K (1984): Possible relationship between receptor reserve and the differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated pressor responses by calcium channel antagonists in the pithed rat. J Pharmacol Exp Ther 230:587-594.
303. 1-Adrenoceptors: Recent developments. Med Res Rev 14:229-270.
304. Ruffolo RR Jr, Bondinell WE, Hieble JP (1995a): α- and β-Adrenoceptors: From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem 38:3415-3444.
305. 1-Adrenoceptors: Pharmacological classification and newer therapeutic applications. Proc West Pharmacol Soc 38:121-126.
306. 1-adrenoceptors in rat myocardial tissue after alkylation with phenoxybenzamine. Eur J Pharmacol 266:35-42.
307. Sattar MA, Johns EJ (1996): Alpha-1 adrenoceptor subtypes involved in mediating adrenergically induced antinatriuresis and antidiuresis in two kidney, one clip Goldblatt and deoxycorticosterone acetatesalt hypertensive rats. J Pharmacol Exp Ther 277:245-252.
308. 2-adrenoceptor agonist: a review of its pharmacodynamic effects. Prog Neuro-Psychopharmacol Biol Psychiatr 13:635-651.
309. Schirger A, Sheps SG, Thomas JE, Fealey RD (1981): Midodrine: A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome, Mayo Clin Proc 56:429-433.
310. 1A-adrenoceptor antagonist: Analysis of a multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29:145-154.
311. Schwietert HR, Wilhelm D, Wilffert B, van Zwieten PA (1991): Differences between full and partial α-adrenoceptor agonists in eliciting phasic and tonic types of responses in the longitudinal smooth muscle of the rat portal vein. Naunyn-Schmiedeberg Arch Pharmacol 344:206-212.
312. Schwinn DA (1993): Adrenoceptors as models for G protein-coupled receptors: Structure, function and regulation. Br J Anaesth 71:77-85.
313. 1-adrenergic receptor subtype. J Biol Chem 265:8183-8189.
314. 1c-adrenergic receptor: Characterization of signal transduction pathways and mammalian tissue heterogeneity. Mol Pharmacol 40:619-626.
315. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, Peter B, Bailey DS (1995): Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: Sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther 272:134-142.
316. Shihasaki M, Sudoh K, Inagaki O, Uchida W, Honda K (1992): Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs. J Anton Pharmacol 12:263-268.
317. 1-adrenoceptors and native tissues. Mol Pharmacol 48:250-258.
318. Shoji T (1981): Comparison of pre- and post-synaptic α-adrenoceptor blocking effects of E-643 in the isolated vas deferens of the rat. Jap J Pharmacol 31:361-368.
319. 1-adrenoceptor agonist action of chloroethylclonidine in the rat anococcygeus muscle. Br J Pharmacol 110 (Suppl):125.
320. 1B-adrenoceptors. Eur J Pharmacol 238:407-410.
321. Smith DJ, Chapple CR, Marshall I, Burt RR Andersson PO, Greengrass PM, Wyllie MG (1993): Human alpha lc-adrenoceptors: Functional characterisation in the human prostate. J Urol 149:434A.
322. 1-adrenoceptor antagonist) and the role of α-adrenoceptor stimulation and blockade on atrioventricular conduction. J Cardiovasc Pharmacol 16:824-830.
323. Stanisic D, Hancock AA, Meyer M, DeBernardis JF (1988): Stereoselective discrimination of serotoninergic 5HT-1A and 5HT-1B binding sites using the enantiomers of spiroxatrine and WB-4101. FASEB J 2:A-1399.
324. 1-adrenoceptor antagonist. J Cardiovasc Pharmacol 11:387-395.
325. Starke K, Montel J, Gayk W, Merker R (1974): Comparison of the effects of clonidine on pre- and post-synaptic adrenoceptors in the rabbit pulmonary artery. Naunyn-Schmiedeberg Arch Pharmacol 285:133-150.
326. Strader CD, Fong TM, Tota MR, Underwood D, Dixon RAF (1994): Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132.
327. Strader CD, Fong TM, Candelore MR, Cascieri MA, Weinberg D, Bayne M (1995): Adrenergic receptors as models for the family of G protein coupled receptors. Pharmacol Commun 6:195-202.
328. 1-adrenoceptor antagonist, on urethral pressure profile in anaesthetized dogs. J Auton Pharmacol 16:147-154.
329. 1-adrenoceptors. Life Sci 45:2577-2585.
330. 1-adrenoceptors of rabbit and rat liver membranes. Life Sci 53:PL 177-PL 181.
331. 1-Adrenoceptor subtype affinities of tamsulosin metabolites. Br J Pharmacol 116:207P.
332. 1A-Adrenoceptors in rabbit bronchus. Eur J Pharmacol 202:281-283.
333. 1-adrenoceptor antagonist. Yakugaku Zasshi 115:773-789.
334. 1-adrenoceptor antagonistic, and antidyslipidemic effects. Cardiovasc Drug Rev 12:254-269.
335. 2-adrenergic receptors by benextramine. Mol Pharmacol 31:89-96.
336. 1-adrenoceptor subtypes in human prostate: Comparison with those in rat vas deferens and spleen. Eur J Pharmacol 265:61-66.
337. 1-adrenoceptors in the reduction of external carotid blood flow induced by buspirone and ipsapirone in the dog. Life Sci 58:63-73.
338. 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 249:307-315.
339. 1-antagonist selective for the lower urinary tract: In vitro studies. Neurourol Urodyn 13:473-474.
340. 1-antagonist selective for the lower urinary tract: In vivo studies. Neurourol Urodyn 13:471-473.
341. 1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta. Life Sci 57:PL 159-PL 163.
342. 1-adrenoceptor antagonist. Pharmacol Commun 6:79-86.
343. Testa R, Guarneri L, Taddei C, Poggesi E, Angelico P , Sartani A, Leonards A, Gofrit ON, Meretyk S, Gaine M (1996): Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther 277:1237-1246.
344. 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man. Br J Clin Pharmacol 33:405-409.
345. 1-adrenoceptor agonists by the inhibition of its pressor responses by calcium entry blockade and vasodilatation in pithed rats and cats. Eur J Pharmacol 96:187-192.
346. 1B-adrenoceptors. Mol Pharmacol 42:403-406.
347. 1c-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol 115:1475-1485.
348. 1-adrenoceptor agonist, SDZ NV1-085, behaves as a potent, competitive antagonist of 5-hydroxytryptamine-induced contraction of rat aorta. Eur J Pharmacol 287:309-312.
349. 1-adrenoceptor antagonists in rat aorta. Br J Pharmacol 118:299-310.
350. 1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery. Br J Pharmacol 118:1308-1316.
351. Vargas HM, Gorman AJ (1995): Vascular alpha-l adrenergic receptor subtypes in the regulation of arterial blood pressure. Life Sci 57:2291-2308.
352. 1B-adrenoceptor antagonist in the unanesthetized rat: A pharmacological analysis in vivo and in vitro. J Pharmacol Exp Ther 266:864-871.
353. 1-adrenoceptor subtype affinities. Br J Pharmacol 116:20P.
354. Vincent J, Hamilton CA, Reid JL (1986): The cardiovascular effects of trimazosin and prazosin in the rabbit. Clin Exp Pharmacol Physiol 13:593-608.
355. 1-adrenoceptors. Eur J Pharmacol 91:377-381.
356. 1C- Biochem Biophys Res Commun 201:1296-1304.
357. 3H]WB-4101) to multiple sites in human brain. Biochem Pharmacol 30:3115-3120.
358. 2+ channel antagonist niguldipine. J Med Chem 38:1579-1581.
359. Wilde MI, Fitton A, McTavish D (1993): Alfuzosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 45:410-429.
360. 3H]dihydroergocryptine binding. Science 192:791-793.
361. 1a-Adrenergic receptor mediated positive chronotropic effect in right atria isolated from rats. Can J Physiol Pharmacol 72:1574-1579.
362. Wong PC, Aldrich PE, Chiu AT, Earl RA, Hart SD, Johnson AL, Ma P, McCall DE, Price WA Jr, Smith RD, Wexler RR, Timmermans PBMWM (1993): Pharmacology of 2-amino-l,4-dihydro-4-(2-{4-[4-(2-methoxyphenyl)-l-piperazinyl] butylsulfinyl} phenyl) -6-methyl-5-nitro-3-pyridine carboxylic acid methyl ester (XB513), a novel calcium agonist with alpha-1 adrenergic receptor antagonistic property. J Pharmacol Exp Ther 265:1088-1095.
363. 1-AR) with chloroethylclonidine (CEC): A kinetic analysis. FASEB J 10:A418.
364. 1 adrenoceptors in human prostates. J Urol 146:877-880.
365. 1-adrenoceptors in benign prostatic hypertrophy. Life Sci 50:127-135.
366. 1-antagonists. Life Sci 54:1845-1854.
367. 1-adrenoceptors in human prostates with benign prostatic hypertrophy. Urol Res 22:273-278.
368. Yamaguchi T, Kitada S, Osada Y (1993): Role of adrenoceptors in the proximal urethral function of female and male rabbits using an in vivo model of isovolumetric pressure generation. Neurourol Urodyn 12:49-57.
369. 1 adrenergic stimulation: A potential role for receptor mediated activation of sarcolemmal sodium-hydrogen exchange. Cardiovasc Res 29:222-230.
370. 3H](o-ethoxyphenoxy)ethyl]amino]-propyl]-2-methoxybenzenesulfonamide HCL, a potent and selective alpha-1 adrenoceptor radioligand. J Pharmacol Exp Ther 263:201-206.
371. Yoshioka M, Togashi H, Abe M, Ikeda T, Matsumoto M, Saito H (1990): Central sympathoinhibitory action of a new type of alpha-1 adrenoceptor antagonist, YM-617in rats. J Pharmacol Exp Ther 253:427-431.
372. Young ML, Su MJ, Wu MH, Chen CC (1994): The electrophysiological effects of dicentrine on the conduction system of rabbit heart. Br J Pharmacol 113:69-76.
373. 1-adrenoceptor antagonist: Comparison with prazosin in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Br J Pharmacol 106:797-801.
374. 1-adrenoceptor antagonist, on human hyperplastic prostates. Eur J Pharmacol 252:29-34.
375. Zhou L, Vargas HM (1996a): Pharmacological studies on the potency and selectivity of BMY 7378 for alpha-1 adrenoceptor (AR) subtypes in pithed rat. FASEB J 10:A425.
376. 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Eur J Pharmacol 305:173-176.